REG - Destiny Pharma PLC - Posting of Annual Report and Notice of AGM

Destiny PharmaAnnouncement

09/05/2024 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240509:nRSI8522Na&default-theme=true

RNS Number : 8522N  Destiny Pharma PLC  09 May 2024

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Posting of Annual Report and Accounts, and Notice of AGM

 

 

Brighton, United Kingdom - 9 May 2024 - Destiny Pharma plc (AIM: DEST) a
clinical stage innovative biotechnology company focused on the development of
novel medicines that can prevent life-threatening infections, announces that
the following documents are now available on the Company's website at
www.destinypharma.com (http://www.destinypharma.com) :

 

·      Annual Report and Accounts of the Company for the year ended 31
December 2023

 

·      Notice of the 2024 Annual General Meeting ("AGM") and details for
voting by proxy, which is to be held at 11.00 a.m. on 12 June 2024 at the
offices of Covington & Burling LLP, 22 Bishopsgate, London, EC2N 4BQ

 

Printed copies of both documents will be posted to shareholders today.

 

Immediately following the AGM at 11:00am, Destiny Pharma will host a live
presentation followed by Q&A.

 

In order to ensure that shareholders are able to follow the proceedings of the
AGM without attending in person, the Company will provide access online via
the Investor Meet Company platform. However, please note that shareholders
will not be able to vote online at the AGM via the platform and are therefore
requested to submit their votes via proxy, as early as possible. Shareholders
are invited to submit any questions for the Board to consider. Questions can
be pre submitted ahead of the AGM via the Investor Meet Company Platform up
until 9 a.m. the day before the AGM or submitted at any time during the AGM
itself.

 

Shareholders that wish to attend the AGM remotely should register for the
event in advance by using the following
link:https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
(https://url.avanan.click/v2/___https:/www.investormeetcompany.com/destiny-pharma-plc/register-investor___.YXAxZTpzaG9yZWNhcDphOm86ZDA0NmQ3NTM5NWRhOTZlNDM0ZDBkZGUxNTQyN2ZiNWQ6NjphZjJiOmE5NjUyM2MyZGY1MzllZmIzNmVjNzYwMjRmMDc1ZGJlZThkMWE1NmRkZjMzN2M0YzAwNzllMDRjOGM2N2M5NTA6cDpG)

 

 

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com (mailto:pressoffice@destinypharma.com)

 

FTI Consulting

Ben Atwell / Simon Conway / Michael Trace

+44 (0) 203 727 1000

destinypharma@fticonsulting.com (mailto:destinypharma@fticonsulting.com)

 

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

 

About Destiny Pharma

 

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development pipeline includes
two late-stage assets: XF-73 nasal gel, a proprietary drug targeting
the prevention of post-surgical staphylococcal hospital infections including
MRSA and NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAALMJTMTJMBMI